Objective: Iridocorneal angle (ICA) narrowing is a known risk factor for primary glaucoma in multiple species, but has not been described in companion rabbits. This study aimed to develop an ICA grading scheme for companion rabbits to enable early glaucoma predisposition diagnosis. Animals studied: Twenty healthy rabbits of varying breeds and ages. Procedures: Rabbits received complete ophthalmic examinations, including gonioscopy, and imaging of the ICA using spectral-domain optical coherence tomography (SD-OCT), Scheimpflug imaging (Pentacam ® HR), and high-resolution ultrasound (HRUS). Angle opening distance (AOD) and angle recess area (ARA) of the ICA were measured and assessed for agreement using a Bland-Altman analysis. A fivestage gonioscopy grading scheme was created, and Spearman-rank test assessed for correlation between gonioscopy grades and ICA measurements. Differences among age and sex were analyzed with a nonparametric ANOVA and Wilcoxon rank-sum test, respectively. Results: Analysis revealed AOD medians of 0.28mm for SD-OCT [95% CI: 0.24-0.31], 0.20mm for Pentacam ® HR [95% CI: 0.18-0.21], and 0.25mm for HRUS [95% CI: 0.22-0.28]. The median ARA was 0.14mm 2 for SD-OCT [95% CI: 0.117-0.163], 0.09mm 2 for Pentacam ® HR [95% CI: 0.082-0.100], and 0.06mm 2 for HRUS [95% CI: 0.046-0.054]. The association between gonioscopy grade and SD-OCT ARA was significant (P < 0.05), and there was a significant difference (P < 0.001) between imaging modalities for both ARA and AOD. Conclusions: Gonioscopy grade correlated well with SD-OCT ARA. Therefore, SD-OCT is recommended as a noncontact method for evaluating companion rabbit ICA.Each imaging device should not be used interchangeably for ICA evaluation. K E Y W O R D S gonioscopy, iridocorneal angle, rabbit, Scheimpflug imaging, SD-OCT, ultrasound | 835 LI PUMA et AL.

This study evaluated cataracts in wild boar exposed to chronic low-dose radiation. We examined wild boar from within and outside the Fukushima Exclusion Zone for nuclear, cortical, and posterior subcapsular (PSC) cataracts in vivo and photographically. Plausible upper-bound, lifetime radiation dose for each boar was estimated from radioactivity levels in each animal's home range combined with tissue concentrations of 134+137 Cesium. Fifteen exposed and twenty control boar were evaluated. There were no significant differences in overall prevalence or score for cortical or PSC cataracts between exposed and control animals. Nuclear (centrally located) cataracts were significantly more prevalent in exposed boar (p < 0.05) and had statistically higher median scores. Plausible upper-bound, lifetime radiation dose ranged from 1 to 1,600 mGy in exposed animals, with no correlation between dose and cortical or PSC score. While radiation dose and nuclear score were positively associated, the impact of age could not be completely separated from the relationship. Additionally, the clinical significance of even the highest scoring nuclear cataract was negligible. Based on the population sampled, wild boar in the Fukushima Exclusion Zone do not have a significantly higher prevalence or risk of cortical or PSC cataracts compared to control animals.

The present study aimed to describe the use of systemic mycophenolate as a steroid‐sparing therapy for immune‐mediated ophthalmic disease. Records for canine patients with suspected or confirmed immune‐mediated ophthalmic disease were retrospectively reviewed for patient signalment, diagnoses, mycophenolate dose, concurrent medications, reported side effects, and long‐term outcome while receiving systemic mycophenolate. Patient diagnoses included: anterior uveitis, panuveitis, presumed immune‐mediated retinopathy, retinal detachment, chorioretinitis, optic neuritis, and/or uveodermatologic syndrome. Overall, 18 of 23 (78%) patients had either a complete or partial response to therapy. Only six of 18 (33%) patients with a complete or partial response to therapy continued to require adjunct systemic immunosuppressive/anti‐inflammatory therapy. Gastrointestinal side effects were reported in five of 23 (22%) patients; one of these cases resolved with a 50% mycophenolate dose decrease while maintaining good control of intraocular inflammation. In conclusion, systemic mycophenolate may be considered as an adjunct or sole therapy for medical management of canine immune‐mediated ophthalmic disease.

No abstract